• Explore /
  • Poster
  • / KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations.

Abstract Poster

Authors

Sun Young Rha

Sun Young Rha

Yonsei Cancer Center, Yonsei University Health System, Seoul, Korea, Republic of (South)

Sun Young Rha , Lucjan Wyrwicz , Patricio Eduardo Yanez Weber , Yuxian Bai , Min-Hee Ryu , Jeeyun Lee , Fernando Rivera , Gustavo Vasconcelos Alves , Marcelo Garrido , Kai-Keen Shiu , Manuel González Fernández , Jin Li , Maeve Aine Lowery , Timucin Cil , Felipe Melo Cruz , Shukui Qin , Lina Yin , Sonal Bordia , Pooja Bhagia , Do-Youn Oh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03675737

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 4014)

DOI

10.1200/JCO.2023.41.16_suppl.4014

Abstract #

4014

Poster Bd #

334

Abstract Disclosures

Similar Posters

First Author: Josep Tabernero

First Author: Zev A. Wainberg

First Author: Joseph Chao

First Author: Yelena Y. Janjigian